All HC readers should take note GSK reported Relenza sales at $28.3m (13 million GBP) compare to Peter Cook’s announcement of $20.8 million. By all account, the sale of Relenza Call options where BTA received zero royalty is the most likely reason for the missing $7.5M.
Relenza call options could possibly account for 27% of GSK Relenza sales. GSK did not put a sales figure to the UK order BUT Peter Cook ESTIMATED it to be $18M royalties on the assumption that there is no Call Option in the order.
The recent sales reports indicate the cooked $18M may only be $13 million in royalties (73% of $18M).
- Forums
- ASX - By Stock
- sales figure for relenza call options
All HC readers should take note GSK reported Relenza sales at...
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online